Lotilaner ophthalmic not checked

Tarsus Pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days”In the company’s words, NCT06182358 on ClinicalTrials.gov
Tested for
Demodex Blepharitis
Main trialPhase 4
“To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.”In the company’s words, NCT06182358 on ClinicalTrials.gov

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 4Completed 27 Jan 2025 Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Lotilaner ophthalmic

Following is part of Solo: you see every change to Lotilaner ophthalmic the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in